Manhattan BioSolutions, Inc.

Collaborative research between Manhattan BioSolutions and the Institute of Chemical Biology & Drug Discovery (ICB&DD) at Stony Brook University will advance next-generation ADC platform using novel TxD payloads

Manhattan BioSolutions Secures Expanded Rights to Novel Legumain-Cleavable Topoisomerase 1 inhibitor (TOP1i) ADC Platform After Successful Multi-Target Validation

Manhattan BioSolutions, Inc. ("MABS"), an emerging biotechnology company developing new classes of precision biologics that harness natural host defense mechanisms, today announced that its RNA-targeting therapeutic, MABS-139, will be evaluated in...

Manhattan BioSolutions, Inc. (MABS), an emerging biotech company developing new classes of precision biologics for the treatment of advanced cancers, and the Institute of Chemical Biology & Drug Discovery (ICB&DD) at Stony Brook University, led...

Manhattan BioSolutions, Inc. ("Manhattan Bio"), an emerging biotechnology company developing new classes of precision biologics for the treatment of advanced cancers, today announced a collaborative poster presentation at the American Association for...

Manhattan BioSolutions, Inc. (Manhattan Bio or MABS), an emerging biotech company developing innovative precision biologics, today announced its selection as an awardee of the Science in the City QuickFire Challenge launched by Johnson & Johnson...